Loss of PTEN has been associated with an increase of PD-L1 on glioblastoma cells and immune resistance29–31 and in clinical trials resistance to PD-1 inhibitors is associated with genetic alterations in the PTEN gene25. This evidence concerns the gene PTEN and glioblastoma.